melflufen: Clinical Trials

6 trials of melflufen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 terminated, 1 completed, 1 withdrawn. 6 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Terminated 4, Completed 1, Withdrawn 1
Phase 12Terminated 2

Follow melflufen: new trials by email Literature Review of melflufen trials Research Report on melflufen

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Melflufen for Elderly Patients With Relapsed Myeloma
Melflufen, Dexamethasone - Relapse Multiple Myeloma
Phase 2WithdrawnFondazione EMN Italy Onlus2025-03-262025-04-01
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
Melphalan, Dexamethasone - RRMM
Phase 2TerminatedOncopeptides AB272020-08-042023-03-09
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
Melflufen, Dexamethasone - Renal Impairment, Multiple Myeloma
Phase 2TerminatedOncopeptides AB352018-08-282023-03-10
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib - Multiple Myeloma
Phase 1 / Phase 2TerminatedOncopeptides AB562018-04-122022-12-19
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Melphalan flufenamide (Melflufen), Dexamethasone - Multiple Myeloma
Phase 2CompletedOncopeptides AB1572016-12-282022-11-22
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Melflufen, Dexamethasone - Relapsed and/or Relapsed-refractory Multiple Myeloma
Phase 1 / Phase 2TerminatedOncopeptides AB752013-07-012020-10-23

Conditions studied

Multiple Myeloma (3)  ·  Renal Insufficiency (1)

Sponsors

Oncopeptides AB (5)  ·  Fondazione EMN Italy Onlus (1)

Countries

United States (4)  ·  Czechia (3)  ·  Italy (3)  ·  France (2)  ·  Spain (2)  ·  Bulgaria (1)  ·  Denmark (1)  ·  Greece (1)  ·  Hungary (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Sweden (1)  ·  Ukraine (1)

Top investigators

Johan Harmenberg, MD (1)  ·  Johan Harmenberg, MD, PhD (1)  ·  Paul G Richardson, MD (1)

Results publications

PMID 32213344, PMID 33296242, PMID 34671975, PMID 37355418

NIH funding

2018 (1)